Kaskela Law LLC is investigating Nautilus Biotechnology, Inc. (NASDAQ: NAUT) on behalf of the company’s former employees.
On July 15, 2021, Arya Sciences Acquisition Corp. III (“Arya”), a publicly traded special purpose acquisition (“SPAC”) company, announced that Arya’s stockholders had approved of an acquisition of privately held Nautilus Biotechnology, Inc. (“Legacy Nautilus”). Arya also announced that, upon the closing of the acquisition, the combined company would continue to be named Nautilus Biotechnology (“Nautilus”) and its common stock would start trading under ticker symbol NASDAQ: NAUT.
In connection with the closing of the acquisition, many of Legacy Nautilus’s executives and employees had their previously held shares/stock options of privately held Legacy Nautilus converted into shares of publicly traded Nautilus (NASDAQ: NAUT). The investigation seeks to determine whether this share conversion was done in a fair manner and in accordance with the securities laws, or whether former Legacy Nautilus shareholders were financially harmed in connection with the conversion.
Former Legacy Nautilus employees who had their shares/stock options of privately held Legacy Nautilus converted into publicly traded shares of Nautilus (NASDAQ: NAUT) are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (484) 229 – 0750, or by completing the form on this page, to receive additional information about this investigation and their legal rights and options.
CONTACT:
KASKELA LAW LLC
D. Seamus Kaskela, Esq.
([email protected])
Adrienne Bell, Esq.
([email protected])
18 Campus Blvd., Suite 100
Newtown Square, PA 19073
(888) 715 – 1740
(484) 229 – 0750